From Pediatric Cancer Challenges to CAR T Cell Signaling with Robbie Majzner, MD

In this episode, Robbie Majzner, MD, a PICI Investigator at the Dana-Farber Cancer Institute, sits down with PICI Chief Scientific Officer John Connolly, PhD, to discuss efforts to engineer next-generation CAR T cells using synthetic biology to enhance the therapeutic potential for fatal pediatric cancers. Formerly a researcher at Stanford University, where he was mentored by Crystal Mackall, MD, Center Director for the PICI Center at Stanford Medicine, Robbie is among the founding members of Cargo Therapeutics, a PICI investment company. 

Listen as Robbie covers collaboration in the pediatric oncology field, the distinct characteristics of pediatric cancers and their immuno-biology versus adult cancers, and drug development obstacles for children.  

Get ready to go from bench to fireside with Robbie Majzner, MD.

++

From Bench to Fireside™ is a new podcast from the Parker Institute for Cancer Immunotherapy (PICI) that takes you from behind the lab bench to the frontiers of cancer research. Each episode features an interview with members of the PICI Network, pioneers in cancer immunotherapy and leaders at world-renowned cancer research institutions. Throughout the conversations, these experts weigh in on the potential of the human immune system to target and eradicate cancer cells, from the latest breakthroughs in immuno-oncology to their impact on patients. Along the way, they unpack the hurdles encountered and the opportunities that lie ahead.

Tune in to hear from scientific leaders who stand at the forefront of developing breakthrough immune therapies with the goal of turning all cancers into curable diseases. 

From Bench to Fireside™ is produced by the Parker Institute for Cancer Immunotherapy. Follow PICI on LinkedIn, X @parkerici or visit www.parkerici.org.